litlas
ログインアカウント作成

Daniel P. Petrylak

1992–2025 年に発表

179
論文数
39,814
被引用数
86
h 指数
171
i10 指数

被引用数

Daniel P. Petrylak の年別被引用数1896 年: 被引用 1 件1992 年: 被引用 1 件1993 年: 被引用 2 件1994 年: 被引用 3 件1995 年: 被引用 7 件1996 年: 被引用 6 件1997 年: 被引用 12 件1998 年: 被引用 13 件1999 年: 被引用 25 件2000 年: 被引用 22 件2001 年: 被引用 51 件2002 年: 被引用 45 件2003 年: 被引用 52 件2004 年: 被引用 51 件2005 年: 被引用 78 件2006 年: 被引用 69 件2007 年: 被引用 106 件2008 年: 被引用 98 件2009 年: 被引用 133 件2010 年: 被引用 124 件2011 年: 被引用 130 件2012 年: 被引用 73 件2013 年: 被引用 106 件2014 年: 被引用 131 件2015 年: 被引用 216 件2016 年: 被引用 349 件2017 年: 被引用 494 件2018 年: 被引用 498 件2019 年: 被引用 1,298 件2020 年: 被引用 1,666 件2021 年: 被引用 1,759 件2022 年: 被引用 1,467 件2023 年: 被引用 1,263 件2024 年: 被引用 2,111 件2025 年: 被引用 961 件2026 年: 被引用 24 件1897〜1991 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 4,223 件、この内訳の 26%中国: 引用元論文 1,873 件、この内訳の 11.5%イギリス: 引用元論文 957 件、この内訳の 5.9%イタリア: 引用元論文 921 件、この内訳の 5.7%ドイツ: 引用元論文 800 件、この内訳の 4.9%フランス: 引用元論文 783 件、この内訳の 4.8%カナダ: 引用元論文 652 件、この内訳の 4%日本: 引用元論文 586 件、この内訳の 3.6%スペイン: 引用元論文 573 件、この内訳の 3.5%オランダ: 引用元論文 429 件、この内訳の 2.7%オーストラリア: 引用元論文 397 件、この内訳の 2.5%スイス: 引用元論文 382 件、この内訳の 2.4%
0%26%その他 22.5%

機関

分野

  • Medicine78.4%
  • Biochemistry, Genetics and Molecular Biology14.4%
  • Immunology and Microbiology4.2%
  • Engineering0.8%
  • Materials Science0.4%
  • Mathematics0.3%
  • その他1.5%

トピック

  • Cancer Immunotherapy and Biomarkers12.2%
  • Prostate Cancer Treatment and Research8%
  • Bladder and Urothelial Cancer Treatments6.5%
  • Prostate Cancer Diagnosis and Treatment4.1%
  • Immunotherapy and Immune Responses4%
  • Urinary and Genital Oncology Studies2.8%
  • その他62.4%

共著者

全論文

検索で開く
  1. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

    著者: Thomas Powles, Jonathan E. Rosenberg, Guru Sonpavde, Yohann Loriot, Ignacio Durán, Jae‐Lyun Lee, Nobuaki Matsubara, Christof Vulsteke, Daniel Castellano, Chunzhang Wu, Mary S. Campbell, Maria Matsangou, Daniel P. Petrylak - New England Journal of Medicine 2021 被引用: 1,155

  2. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

    著者: Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin - New England Journal of Medicine 2017 被引用: 3,390

  3. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

    著者: Thomas Powles, Se Hoon Park, Éric Voog, Claudia Caserta, Begoña P. Valderrama, Howard Gurney, Haralabos P. Kalofonos, Siniša Radulović, Wim Demey, Anders Ullén, Yohann Loriot, Srikala S. Sridhar, Norihiko Tsuchiya, Evgeny Kopyltsov, Cora N. Sternberg, Joaquim Bellmunt, Jeanny B. Aragon‐Ching, Daniel P. Petrylak, Robert J Laliberte, Jing Wang, Bo Huang, Craig B. Davis, Camilla Fowst, Nuno Costa, John A. Blake-Haskins, Alessandra di Pietro, Petros Grivas - New England Journal of Medicine 2020 被引用: 1,479

  4. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

    著者: Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles, Michiel S. van der Heijden, Arjun Vasant Balar, Andrea Necchi, Nancy A. Dawson, Peter H. O’Donnell, Ani Sarkis Balmanoukian, Yohann Loriot, Sandy Srinivas, Margitta Retz, Petros Grivas, Richard W. Joseph, Matthew D. Galsky, Mark T. Fleming, Daniel P. Petrylak, José Luis Perez‐Gracia, Howard A. Burris, Daniel Castellano, Christina Canil, Joaquim Bellmunt, Dean F. Bajorin, Dorothee Nickles, Richard Bourgon, Garrett M. Frampton, Na Cui, Sanjeev Mariathasan, Oyewale O. Abidoye, Gregg Fine, Robert Dreicer - The Lancet 2016 被引用: 3,714

  5. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

    著者: Arjun Vasant Balar, Matthew D. Galsky, Jonathan E. Rosenberg, Thomas Powles, Daniel P. Petrylak, Joaquim Bellmunt, Yohann Loriot, Andrea Necchi, Jean Hoffman‐Censits, José Luis Perez‐Gracia, Nancy A. Dawson, Michiel S. van der Heijden, Robert Dreicer, Sandy Srinivas, Margitta Retz, Richard W. Joseph, Alexandra Drakaki, Ulka N. Vaishampayan, Srikala S. Sridhar, David I. Quinn, Ignacio Durán, David R. Shaffer, Bernhard J. Eigl, Petros Grivas, Evan Y. Yu, Shi Li, Edward E. Kadel, Zachary Boyd, Richard Bourgon, Priti S. Hegde, Sanjeev Mariathasan, AnnChristine Thåström, Oyewale O. Abidoye, Gregg Fine, Dean F. Bajorin - The Lancet 2016 被引用: 2,211

  6. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

    著者: Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak, Arash Rezazadeh Kalebasty, Yohann Loriot, Aude Fléchon, Rohit Jain, Neeraj Agarwal, Manojkumar Bupathi, Philippe Barthélémy, Philippe Beuzeboc, Phillip L. Palmbos, Christos E. Kyriakopoulos, Damien Pouessel, Cora N. Sternberg, Quan Hong, Trishna Goswami, Loretta M. Itri, Petros Grivas - Journal of Clinical Oncology 2021 被引用: 533

  7. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

    著者: Andrew J. Armstrong, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey M. Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, B. Yа. Alekseev, Taro Iguchi, Neal D. Shore, Brad Rosbrook, Jennifer Sugg, Benoît Baron, Lucy Chen, Arnulf Stenzl - Journal of Clinical Oncology 2019 被引用: 1,186

  8. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

    著者: Jonathan E. Rosenberg, Peter H. O’Donnell, Arjun Vasant Balar, Bradley A. McGregor, Elisabeth I. Heath, Evan Y. Yu, Matthew D. Galsky, Noah M. Hahn, Elaina M. Gartner, Juan Pinelli, Shang-Ying Liang, Amal Melhem‐Bertrandt, Daniel P. Petrylak - Journal of Clinical Oncology 2019 被引用: 626

  9. Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

    著者: Christopher Hoimes, Thomas W. Flaig, Matthew I. Milowsky, Terence W. Friedlander, Mehmet Asım Bilen, Shilpa Gupta, Sandy Srinivas, Jaime R. Merchan, Rana R. McKay, Daniel P. Petrylak, Carolyn Sasse, Blanca Homet Moreno, Yao Yu, Anne‐Sophie Carret, Jonathan E. Rosenberg - Journal of Clinical Oncology 2022 被引用: 267

  10. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

    著者: Xīn Gào, Howard A. Burris, Jacqueline Vuky, Robert Dreicer, Oliver Sartor, Cora N. Sternberg, Ivor Percent, Maha Hussain, Arash Rezazadeh Kalebasty, John Shen, Elisabeth I. Heath, Guillermo Abesada‐Terk, Sunil Gandhi, Meredith McKean, Haolan Lu, Elmer Berghorn, Richard Gedrich, S. Debbie Chirnomas, Nicholas J. Vogelzang, Daniel P. Petrylak - Journal of Clinical Oncology 2022 被引用: 186

  11. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    著者: Thomas Powles, Joseph P. Eder, Gregg Fine, Fadi S. Braiteh, Yohann Loriot, Cristina Cruz, Joaquim Bellmunt, Howard A. Burris, Daniel P. Petrylak, Siew-leng Melinda Teng, Xiaodong Shen, Zachary Boyd, Priti S. Hegde, Daniel S. Chen, Nicholas J. Vogelzang - Nature 2014 被引用: 2,430

  12. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

    著者: Jonathan E. Rosenberg, Srikala S. Sridhar, Jingsong Zhang, David C. Smith, Dean Ruether, Thomas W. Flaig, Joaquina Baranda, Joshua M. Lang, Elizabeth R. Plimack, Randeep Sangha, Elisabeth I. Heath, Jamie Merchan, David I. Quinn, Sandy Srinivas, Matthew I. Milowsky, Chunzhang Wu, Elaina M. Gartner, Peiying Zuo, Amal Melhem‐Bertrandt, Daniel P. Petrylak - Journal of Clinical Oncology 2020 被引用: 327

  13. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

    著者: Peter H. O’Donnell, Matthew I. Milowsky, Daniel P. Petrylak, Christopher Hoimes, Thomas W. Flaig, Nataliya Mar, Helen Moon, Terence W. Friedlander, Rana R. McKay, Mehmet Asım Bilen, Sandy Srinivas, Earle F. Burgess, Chethan Ramamurthy, Saby George, Daniel M. Geynisman, Sergio Bracarda, Delphine Borchiellini, Lionnel Geoffrois, J.P. Maroto Rey, Christiano Ferrario, Anne‐Sophie Carret, Yao Yu, Maria Guseva, Blanca Homet Moreno, Jonathan E. Rosenberg - Journal of Clinical Oncology 2023 被引用: 175

  14. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    著者: Thomas Powles, Michiel S. van der Heijden, Daniel Castellano, Matthew D. Galsky, Yohann Loriot, Daniel P. Petrylak, Osamu Ogawa, Se Hoon Park, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Aristotelis Bamias, Bernhard J. Eigl, Howard Gurney, Som D. Mukherjee, Yves Fradet, Iwona Skoneczna, Marinos Tsiatas, Andrey Novikov, Cristina Suárez, André P. Fay, Ignacio Durán, Andrea Necchi, Sophie Wildsmith, Philip He, Natasha Angra, Ashok Gupta, Wendy J. Levin, Joaquim Bellmunt, Se Hoon Park, Michiel S. van der Heijden, Andrea Necchi, Daniel Castellano, Aristotelis Bamias, Jae‐Lyun Lee, Ugo De Giorgi, Martin Bögemann, Bernhard J. Eigl, Marinos Tsiatas, Thomas Powles, Andrey Novikov, Iwona Skoneczna, Som D. Mukherjee, Cristina Suárez, Hans M. Westgeest, Yves Fradet, Aude Fléchon, Yen‐Chuan Ou, Inkeun Park, Vsevolod Matveev, Begoña Pérez‐Valderrama, Susanna Cheng, Stephen Jay Frank, Howard Gurney, Urbano Anido, Alketa Hamzaj, Margitta Retz, Srikala S. Sridhar, Giorgio V. Scagliotti, Jens Voortman, B. Yа. Alekseev, Anna Alyasova, B. K. Komyakov, Herlinde Dumez, Michel Pavic, Go Kimura, Atsushi Mizokami, Susanne Osanto, José Ángel Arranz, Djura Piersma, Sang Joon Shin, O. B. Karyakin, Ignacio Delgado, José Luis González, See‐Tong Pang, Anna Tran, Oleg Lipatov, Wen-Pin Su, Thomas W. Flaig, Ajjai Alva, Hwa Park Kyong, Evgeny Kopyltsov, Elena Almagro, M. Doménech, Yen‐Hwa Chang, Brieuc Sautois, Andre Ravaux, Gerasimos Aravantinos, V. Georgoulias, Sasja F. Mulder, Yu Jung Kim, Fabio Kater, Christine Chevreau, Scott T. Tagawa, Paweł Zalewski, Florence Joly, Yohann Loriot, Gencay Hatiboglu, Luca Gianni, Franco Morelli ほか 127 名 - The Lancet Oncology 2020 被引用: 498

  15. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

    著者: Joaquim Bellmunt, Maha Hussain, Jürgen E. Gschwend, Peter Albers, Stéphane Oudard, Daniel Castellano, Siamak Daneshmand, Hiroyuki Nishiyama, Martin Majchrowicz, Viraj Degaonkar, Yi Shi, Sanjeev Mariathasan, Petros Grivas, Alexandra Drakaki, Peter H. O’Donnell, Jonathan E. Rosenberg, Daniel M. Geynisman, Daniel P. Petrylak, Jean Hoffman‐Censits, Jens Bedke, Arash Rezazadeh Kalebasty, Yousef Zakharia, Michiel S. van der Heijden, Cora N. Sternberg, Nicole N. Davarpanah, Thomas Powles - The Lancet Oncology 2021 被引用: 412

  16. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

    著者: Evan Y. Yu, Daniel P. Petrylak, Peter H. O’Donnell, Jae‐Lyun Lee, Michiel S. van der Heijden, Yohann Loriot, Mark N. Stein, Andrea Necchi, Takahiro Kojima, Michael R. Harrison, Se Hoon Park, David I. Quinn, Elisabeth I. Heath, Jonathan E. Rosenberg, Joyce Steinberg, Shang-Ying Liang, Janet Trowbridge, Mary S. Campbell, Bradley A. McGregor, Arjun Vasant Balar - The Lancet Oncology 2021 被引用: 267

  17. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

    著者: Andrew J. Armstrong, Arun Azad, Taro Iguchi, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey M. Holzbeierlein, Arnauld Villers, Antonio Alcaraz, B. Yа. Alekseev, Neal D. Shore, F. Gómez-Veiga, Brad Rosbrook, Fabian Zohren, Shunsuke Yamada, Gabriel P. Haas, Arnulf Stenzl - Journal of Clinical Oncology 2022 被引用: 299

  18. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

    著者: Jonathan E. Rosenberg, Thomas Powles, Guru Sonpavde, Yohann Loriot, Ignacio Durán, J.-L. Lee, Nobuaki Matsubara, Christof Vulsteke, Daniel Castellano, Ronac Mamtani, Chunzhang Wu, Maria Matsangou, Mary S. Campbell, Daniel P. Petrylak - Annals of Oncology 2023 被引用: 153

  19. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

    著者: Daniel P. Petrylak, Catherine M. Tangen, Maha Hussain, Primo N. Lara, Jeffrey A. Jones, Mary Ellen Taplin, Patrick A. Burch, Donna L. Berry, Carol M. Moinpour, Manish Kohli, Mitchell C. Benson, Eric J. Small, Derek Raghavan, E. David Crawford - New England Journal of Medicine 2004 被引用: 3,687

  20. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

    著者: Yves Fradet, Joaquim Bellmunt, David J. Vaughn, J L Lee, Lawrence Fong, Nicholas J. Vogelzang, M.Á. Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, K. Nam, Tara L. Frenkl, Rodolfo F. Perini, Ronald de Wit, Dean F. Bajorin - Annals of Oncology 2019 被引用: 488

  21. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

    著者: Susan Halabi, William Kevin Kelly, Hua Ma, Hao Zhou, Nicole Solomon, Karim Fizazi, Catherine M. Tangen, Mark Rosenthal, Daniel P. Petrylak, Maha Hussain, Nicholas J. Vogelzang, Ian M. Thompson, Kim N., Johann S. de Bono, Andrew J. Armstrong, Mario A. Eisenberger, Abderrahim Fandi, Shaoyi Li, John C. Araujo, Christopher J. Logothetis, David I. Quinn, Michael J. Morris, Celestia S. Higano, Ian F. Tannock, Eric J. Small - Journal of Clinical Oncology 2016 被引用: 463

  22. First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).

    著者: Daniel P. Petrylak, Xīn Gào, Nicholas J. Vogelzang, Mary Harlow Garfield, I Taylor, Marcia Dougan Moore, Ronald A. Peck, Howard A. Burris - Journal of Clinical Oncology 2020 被引用: 165

  23. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

    著者: Andrea Necchi, Richard W. Joseph, Yohann Loriot, Jean Hoffman‐Censits, José Luis Perez‐Gracia, Daniel P. Petrylak, Christina Louise Derleth, Darren Tayama, Qingqing Zhu, Beiying Ding, Constanze Kaiser, Jonathan E. Rosenberg - Annals of Oncology 2017 被引用: 322

  24. Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

    著者: Arjun Vasant Balar, Daniel Castellano, Petros Grivas, David J. Vaughn, Thomas Powles, Jacqueline Vuky, Yves Fradet, Jia-Lin Lee, Lawrence Fong, Nicholas J. Vogelzang, José A. Martínez-Climent, Andrea Necchi, Daniel P. Petrylak, Elizabeth R. Plimack, Jin Xu, Kazuo Imai, Blanca Homet Moreno, Joaquim Bellmunt, Ronald de Wit, Peter H. O’Donnell - Annals of Oncology 2022 被引用: 114